Register for our free email digests:
Division of Amgen Inc.
Latest From McNeil Consumer Healthcare
Dermatology OTC switch products for acne, eczema and psoriasis are likely to emerge, says Kline analyst Laura Mahecha. Switches, the return of recalled OTC brands and market consolidation drove a 4.2% increase for the US consumer health market in 2015.
DSE Healthcare substantiates online claims that the Prelief supplement “does not predispose” to problems associated with use of PPIs and beta blockers, NAD says, but advises the firm to discontinue broad acid-removal and symptom-cessation claims.
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.
- Large Molecule
- Therapeutic Areas
- Micromet AG
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Patrick A Baeuerle, PhD, SVP, CSO
Jan Fagerberg, MD, PhD, SVP, CMO
Joseph Lobacki, Chief Commercial Officer
- Contact Info
Phone: (240) 752-1420
9201 Corp. Blvd.
Rockville, MD 20850
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.